Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Circulation|March 2, 2016
Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both WorldsRobert J Mentz, Adrian F Hernandez, Lisa G Berdan, et al.
Trials|July 20, 2021
The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary StudyEmily C O'Brien, Sudha R Raman, Alicia Ellis, et al.
Journal of Clinical and Translational Science|October 30, 2019
Facilitating translational team science: The project leader modelLynn Sutton, Lisa G Berdan, Jean Bolte, et al.
Contemporary Clinical Trials|January 12, 2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialKenneth W Mahaffey, June L Wampole, Amanda Stebbins, et al.
Journal of the American College of Cardiology|October 2, 2002
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT studyLaura S Fernandes, James E Tcheng, J Conor O'Shea, et al.
American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.
JAMA|November 24, 2005
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey, Marc Cohen, Jyotsna Garg, et al.
American Heart Journal|December 13, 2006
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trialHarvey D White, Neal S Kleiman, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|June 14, 2005
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromesKenneth W Mahaffey, Matthew T Roe, Rakhi Kilaru, et al.
The American Journal of Cardiology|November 7, 2009
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)Jason P Linefsky, Min Lin, Karen S Pieper, et al.
Pageof 2